Marksans Pharma Limited (NSE:MARKSANS)

Marksans Pharma Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 16, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Capitalization	137,331	71,097	100,815	68,836	31,903	18,627
Market Cap Growth	71.17%	-29.48%	46.46%	115.77%	71.27%	-8.89%
Enterprise Value	131,151	68,000	96,315	63,549	29,746	16,052
Last Close Price	303.05	156.46	221.08	150.64	69.43	44.65

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 16, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	26.59	17.01	26.49	21.94	11.98	9.97
Forward PE	23.44	15.10	21.89	17.73	5.39	5.39
PS Ratio	4.33	2.41	3.84	3.16	1.72	1.25
PB Ratio	4.50	2.33	4.05	3.30	1.81	1.52
P/TBV Ratio	4.80	2.49	4.28	3.51	1.95	1.67
P/FCF Ratio	41.92	21.70	298.76	319.14	17.36	35.20
P/OCF Ratio	29.98	15.52	48.78	29.88	13.44	18.77
PEG Ratio	0.90	0.83	0.90	0.80	0.80	0.80

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 16, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
EV/Sales Ratio	4.13	2.30	3.67	2.92	1.61	1.08
EV/EBITDA Ratio	18.38	12.05	19.06	14.65	9.29	6.68
EV/EBIT Ratio	21.37	13.53	21.44	16.54	10.34	7.50
EV/FCF Ratio	40.03	20.76	285.42	294.63	16.19	30.33

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 16, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.11	0.11	0.13	0.12	0.07	0.09
Debt / EBITDA Ratio	0.48	0.57	0.60	0.53	0.36	0.43
Debt / FCF Ratio	-	1.05	9.54	11.32	0.67	2.09
Net Debt / Equity Ratio	-0.21	-0.21	-0.15	-0.22	-0.34	-0.19
Net Debt / EBITDA Ratio	-0.96	-1.15	-0.76	-1.05	-1.85	-0.98
Net Debt / FCF Ratio	-	-1.98	-11.38	-21.20	-3.23	-4.46
Asset Turnover	-	0.83	0.89	0.89	0.97	1.04
Inventory Turnover	-	1.47	1.64	1.95	2.07	1.76
Quick Ratio	-	3.13	2.64	2.99	3.34	2.09
Current Ratio	-	5.17	4.62	4.78	4.91	3.37
Return on Equity (ROE)	-	15.16%	16.73%	16.35%	17.76%	17.55%
Return on Assets (ROA)	-	8.85%	9.49%	9.86%	9.39%	9.33%
Return on Invested Capital (ROIC)	19.26%	16.70%	18.27%	20.40%	20.94%	18.80%
Return on Capital Employed (ROCE)	-	15.10%	16.30%	16.80%	15.60%	16.70%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 16, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Earnings Yield	3.76%	5.88%	3.77%	4.56%	8.35%	10.03%
FCF Yield	2.39%	4.61%	0.34%	0.31%	5.76%	2.84%
Dividend Yield	0.30%	0.57%	0.36%	0.40%	0.71%	0.55%
Payout Ratio	7.90%	8.67%	7.14%	7.22%	3.82%	5.67%
Buyback Yield / Dilution	-0.22%	-	-	-9.09%	-1.49%	-
Total Shareholder Return	0.08%	0.57%	0.36%	-8.70%	-0.78%	0.55%

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 18, 2026

Data Sources Report a data error